We conducted an extensive assessment and quantification of the reach of the oncology clinical trial supporting infrastructure in the United States (US). While our primary focus was on identifying avenues to expand the reach of neuro-oncology clinical trials, we considered infrastructure layers with important implications for broader cancer research and care. Specifically, we examined the geographic, population, and socioeconomic reach of national collaboratives (including over 1,500 institutions), over 600 academic oncology and neurosurgery training programs, and networks of over 25,000 individual neuro-oncology, neurosurgery, and general oncology (including hematology/medical/gynecological oncology, surgical oncology, and radiation oncology) providers. Our study found that over 57% of the US population lacks direct access to trial-supporting infrastructure. More than 71% of the locations with infrastructure are urban, and over 72% are in socioeconomically-advantaged areas. Our findings reveal critical disparities in oncology care access and suggest actionable strategies to optimize and expand the existing infrastructure’s reach.\

中文翻译：

---

美国神经肿瘤学试验支持基础设施的可用性和可及性存在差异


我们对美国 (US) 肿瘤临床试验支持基础设施的覆盖范围进行了广泛的评估和量化。虽然我们的主要重点是确定扩大神经肿瘤学临床试验范围的途径，但我们考虑了对更广泛的癌症研究和护理具有重要影响的基础设施层。具体来说，我们研究了国家合作机构（包括 1,500 多个机构）、600 多个学术肿瘤学和神经外科培训项目以及超过 25,000 个个人神经肿瘤学、神经外科和普通肿瘤学（包括血液学/内科/妇科肿瘤学、外科肿瘤学和放射肿瘤学）提供者。我们的研究发现，超过 57% 的美国人口无法直接使用试验支持基础设施。超过71%的基础设施地点位于城市，超过72%位于社会经济优势地区。我们的研究结果揭示了肿瘤护理获取方面的严重差异，并提出了优化和扩大现有基础设施覆盖范围的可行策略。\